Genmab is a biotechnology company specializing in the creation and development of differentiated human antibody therapeutics focused on the treatment of cancer. Co.'s proprietary pipeline, includes bispecific T-cell engagers, immune checkpoint modulators, effector function improved antibodies and antibody-drug conjugates. Co. has seven product candidates in clinical development: tisotumab vedotin, epcoritamab, DuoBody-PD-L1x4-1BB (GEN1046), DuoBody-CD40x4-1BB (GEN1042), DuoHexaBody-CD37 (GEN3009), HexaBody-CD38 (GEN3014) and DuoBody-CD3xB7H4 (GEN1047). Co.'s portfolio also includes four antibody technology platforms: DuoBody, HexaBody, DuoHexaBody, and HexElect. The GMAB YTD return is shown above.
The YTD Return on the GMAB YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether GMAB YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the GMAB YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|